Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706087 | 1.00 | CCR2 (0.34) | CCR2PLGAR | |
| SCHEMBL24963541 | 0.88 | CCR2 (0.39) | CCR2 | |
| SCHEMBL24188796 | 0.86 | CCR2 (0.45) | CCR2 | |
| SCHEMBL24189428 | 0.82 | CCR2 (0.38) | CCR2AR | |
| SCHEMBL25766118 | 0.82 | CCR2 (0.38) | CCR2AR | |
| SCHEMBL21164841 | 0.80 | PLG (0.35) | CCR2PLGAR | |
| SCHEMBL25766120 | 0.80 | CCR2 (0.40) | CCR2AR | |
| SCHEMBL12070429 | 0.80 | CCR2 (0.33) | CCR2AR | |
| SCHEMBL12070430 | 0.80 | CCR2 (0.33) | CCR2AR | |
| SCHEMBL30497365 | 0.79 | AR (0.34) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-07-06 | — | — | US | disclosed |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-05-04 | — | — | US | disclosed |
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-02 | — | — | US | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9169240-B2 | Ketone linked benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-20050143320-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6534530-B1 | Administering (benzo)thiazole peptidomimetic as viricide; protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | CCR2 4830/4885PLG 1052/4885AR 3427/4885 |
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | CCR2 4440/4885PLG 297/4885AR 3751/4885 |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | CCR2 4855/4885PLG 1443/4885AR 3103/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | CCR2 4502/4885PLG 429/4885AR 2887/4885 |
| US-20230140238-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CCR2 1926/4885PLG 4503/4885AR 4034/4885 |
| US-20230212116-A1 | SARS-COV-2 MAIN PROTEASE INHIBITORS | ACE2, ACE, TMPRSS2 | CCR2 1612/4885PLG 78/4885AR 2613/4885 |
| US-20050143320-A1 | Protease inhibitors | PREP, SPINT2, SERPINB1 | CCR2 3602/4885PLG 156/4885AR 2682/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CCR2 1926/4885PLG 4503/4885AR 4034/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CCR2 4244/4885PLG 3839/4885AR 4848/4885 |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | CCR2 1926/4885PLG 4503/4885AR 4034/4885 |
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | CCR2 998/4885PLG 83/4885AR 1669/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CCR2 4502/4885PLG 429/4885AR 2887/4885 |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | CCR2 3212/4885PLG 292/4885AR 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.